Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy.

Roberta RobertiLuigi Francesco IannoneCaterina PalleriaCaterina De SarroRocco SpagnuoloMaria Antonietta BarbieriAda VeroAntonia MantiValentina PisanaWalter FriesGianluca TrifiròMaria Diana NaturaleTiziana LarussaAdele Emanuela De FrancescoVincenzo BoscoEugenio Donato di PaolaRita CitraroFrancesco LuzzaLuigi BennardoStefano RodinòPatrizia DoldoEdoardo SpinaEmilio RussoGiovambattista De Sarro

Published in: Current medical research and opinion (2020)

Overall, considering the low rate of AEs reported and discontinuation from therapy, our data seems to confirm the positive beneficial/risk ratio of biologic treatment for IBDs and provide useful data on biologic drugs in gastroenterology.

Keyphrases

rheumatoid arthritis
electronic health record
big data
drug induced
adverse drug
machine learning
emergency department
data analysis
bone marrow